Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer

Author(s): Sombeer Sharma, Aakash Deep*, Avtar C. Rana, Monu Yadav, Arun K. Sharma.

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Cervical cancer is the most prevalent cancer in the world due to unusual extension of cervical cell. Cervical cancer occurs due to exposure of HPV (Human papillomavirus). According to WHO, it is the 4th most ordinary cancer in women. In 2018, approx 6.6% of population was affected around the world and 570,000 new cases were reported. In low and middle-income countries, 90% of cervical cancer deaths occur.

Methods: Despite various factors that cause cervical cancer are included exposure to HPV, dysregulation of CASPASE enzyme, elevated expression of IAPs (Inhibitor apoptotic protein), E6 and E7 gene of HPV, inhibition of p53, BAK, p16 upregulation, CDK-inactivation causing cervical cancer, role of VEGF, role of estrogen and its receptor in cervical cancer.

Results: Cervical cancer can be screened by Pep test. There are various therapies that can be used to treat cervical cancer. As these therapies have various side effects, so the world is moving to herbal formulations to treat cervical cancer.

Conclusion: In this study, we will discuss cervical cancer, its cause, symptoms, pathophysiology and treatments. Early screening and detection can help in reducing the overall burden of cervical cancer in the near future.

Keywords: Cervical cancer, symptoms, pathophysiology, possible treatments, cervical cells, contraceptive pills.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [49 - 61]
Pages: 13
DOI: 10.2174/1573394715666190126142508
Price: $65

Article Metrics

PDF: 6

Special-new-year-discount